| Among the methods of current tumor treatments, the application of monoclonal antibodies and interferon gets more and more attention. In the clinical and basic research, various types of monoclonal antibodies and interferons used alone or in combination with other chemotherapy drugs to treat cancer has made encouraging progress, at the same time, it also faces many problems, such as: the high cost of production, host immune rejection, the result of treatment is not good and so on. To solve these problems, researchers apply themselves to the development of recombinant interferon, the transformation of antibody and optimization program carried out extensive exploration. The development of artificial recombinant interferon has made a number of enhanced biological activity of interferon but also reduce the toxic side effects, it can be said of recombinant interferon cancer treatment in the future another direction of development. Antibodies transformation, the targeting and affinity has always been the focus of the study. Optimization of treatment programs is more of a combination with other treatment methods in order to find a new type of cancer treatment. At the forefront of the biomedical field of gene therapy, through the carrier system (such as adenovirus) to guide therapeutic genes in human cells, so that the somatic cells can express their own bioactive proteins, play a therapeutic role of the targeting protein can be a variety of treatment organically integrated approach to achieve complementary effects.The recent progress of the Herceptin monoclonal antibody in clinical application and research is becoming more and more hot, in the gene level, we change its protein domains, optimize the amino acid codon .So, on the premise of that a higher affinity to HER2 was obtained ,another common high expression of tumor markers has also been very high affinity to VEGF, even with access to a double antibody targeting of HER2 with high expression of VEGF and anti-tumor suppressor is more unique and precise. Secondly, we integrate the genes of highly efficient of anti-tumor human interferon - Novaferon into the modified dual-targeting antibody genes, made of integration of expression cassettes. Finally, this fusion gene was integrated into adenovirus type 5 which has the obvious advantages in gene therapy and most widely used, in his capacity as fusion protein carrying the anti-tumor gene therapy vector system, our antibody - interferon gene into the cells inside the body expression, avoiding the drawbacks of the directly or separatly using of antibody and interferon, and explore a new cancer treatment programs. This topic will be an innovative way of antibody therapy, interferon therapy and gene therapy, and a skillfull combination of the three therapy methods, through the transformation to be dual-targeting antibodies monoclonal antibody gene together with the recombinant interferon genes integrate into the expression box of adenovirus type 5, constructing a adenovirus gene therapy system of dual-targeting antibodies and recombinant interferon fusion expression. Artificial modification of the dual-targeting Herceptin antibody and fusion expression of interferon gene therapy of cancer based on the system to complete the building, access to high-titer recombinant adenovirus, and in vitro 293, L-02 cells and BABL/ C nude mice have obtained a certain amount of antibodies with biological activity - interferon fusion protein expression. In the ELISA test, the expression of antibody part is not high, but the expression of interferon has been reached nanogram (10-9g) level, the maximum reached 9ng/ml, the concentration of the general role of interferon only picogram (10-12g) level. The antibody-interferon fusion protein, in vivo has already been expressed a certain concentrations of interferon, and through the targeting effect of the antibody part,it can be expected to play a good anti-tumor effects.
|
PDF Full Text Request